(Benzoyl peroxide + clindamycin phosphate) is a Small Molecule owned by Bausch Health Companies, and is involved in 6 clinical trials, of which 5 were completed, and 1 is planned.

Benzoyl peroxide has anti-bacterial activity against propionibacterium acnes, the organism implicated in acne vulgaris. It has keratolytic activity and is sebostatic, counteracting the hyperkeratinisation and excessive sebum production associated with acne. Clindamycin penetrates bacteria cell wall resulting in inhibition of protein synthesis. It binds to the 50S ribosomal subunit (specifically to 23s RNA subunit) of susceptible microorganisms and inhibits the translocation of peptides thus interfering with bacterial protein synthesis. Topical clindamycin reduces free fatty acid concentrations on the skin and suppresses the growth of Propionibacterium acnes (Corynebacterium acnes), an anaerobe found in sebaceous glands and follicles.

The revenue for (Benzoyl peroxide + clindamycin phosphate) is expected to reach a total of $92m through 2034. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Benzoyl peroxide + clindamycin phosphate) NPV Report.

(Benzoyl peroxide + clindamycin phosphate) is currently owned by Bausch Health Companies.

(Benzoyl peroxide + clindamycin phosphate) Overview

Benzoyl Peroxide and Clindamycin Phosphate (Benzaclin, Acanya, Onexton) is a fixed dose combination drug, an antibacterial and anti acne agent. It is formulated as gel for topical application. It is indicated for treatment of acne vulgaris.

Bausch Health Companies Overview

Bausch Health Companies (Bausch Health), formerly Valeant Pharmaceuticals International Inc, is engaged in the manufacturing, development, and marketing of a range of medical devices, over-the-counter products (OTC), and pharmaceutical products. Bausch Health offers products for therapy areas related to dermatology, gastroenterology, eye health, neurology, aesthetic devices, dentistry, and consumer health. It offers various generic and branded generic products. Bausch Health has administrative, research and laboratory, marketing, distribution, and warehousing facilities worldwide. The company offers products directly or indirectly in various regions across the world including the US, Canada, Africa, Middle East, Australia, Latin America, and Europe. It also operates manufacturing facilities in the US, Brazil, Columbia, Germany, Canada, among others. Bausch Health is headquartered in Laval, Quebec, Canada.

The company reported revenues of (US Dollars) US$8,434 million for the fiscal year ended December 2021 (FY2021), an increase of 5.1% over FY2020. In FY2021, the company’s operating margin was 4.6%, compared to an operating margin of 7.7% in FY2020. The net loss of the company was US$948 million in FY2021, compared to a net loss of US$560 million in FY2020. The company reported revenues of US$2,046 million for the third quarter ended September 2022, an increase of 4% over the previous quarter.

Quick View – (Benzoyl peroxide + clindamycin phosphate)

Report Segments
  • Innovator (Non-NME)
Drug Name
  • (Benzoyl peroxide + clindamycin phosphate)
Administration Pathway
  • Topical
Therapeutic Areas
  • Dermatology
Key Companies
Highest Development Stage
  • Marketed


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.